Funding news · Sep 21, 2026
Biolevate Raises €30M Series A Led by Aymar Hénin
Biolevate Secures €30M Series A
Biolevate, a Paris-based life sciences AI startup, has raised €30 million in Series A funding. The round was announced on September 21, 2026, and was led by Aymar Hénin.
What the Company Does
Biolevate builds AI for the life sciences. Its core product is the ELISE knowledge platform, which uses natural language processing (NLP) and visual document reading to extract and structure unstructured healthcare and regulatory data.
The platform is aimed at pharmaceutical, MedTech, and cosmetics companies. Key capabilities include:
- Metadata extraction
- Collaborative editing
- Version control
- Regulatory-compliant workflows
According to the company, these capabilities are designed to accelerate R&D and regulatory submissions.
Founding Team
Biolevate was founded in 2023 by Joel Belafa and Nathan Chen.
Round Details
| Item | Detail |
|---|---|
| Round type | Series A |
| Amount | €30,000,000 |
| Currency | EUR |
| Date | September 21, 2026 |
| Lead investor | Aymar Hénin |
| Investors | Aymar Hénin |
Why It Matters
Life sciences organizations generate enormous volumes of unstructured documentation — clinical data, regulatory filings, and internal research materials. Biolevate's ELISE platform targets this problem directly, combining NLP with visual document reading to turn unstructured content into structured, usable data.
The inclusion of version control and regulatory-compliant workflows signals that Biolevate is built for environments where auditability and traceability matter. That positions the company to serve pharmaceutical, MedTech, and cosmetics customers whose R&D and regulatory submission processes are document-intensive and highly regulated.
For acquirers and strategic investors in life sciences software, AI-driven document intelligence, or regulatory technology, Biolevate offers:
- A defined product (ELISE) with a clear technical approach
- A customer focus spanning pharma, MedTech, and cosmetics
- A Paris base within a strong European life sciences and AI ecosystem
- A founding team that has built the company since 2023
The €30 million Series A, led by Aymar Hénin, provides capital to scale the platform and its commercial reach. Specific use of proceeds was not disclosed.
Summary
Biolevate has raised a €30 million Series A led by Aymar Hénin. The Paris-based company, founded in 2023 by Joel Belafa and Nathan Chen, develops the ELISE knowledge platform, which uses NLP and visual document reading to extract and structure unstructured healthcare and regulatory data for pharmaceutical, MedTech, and cosmetics companies.